Soufiane Mourragui

Soufiane Mourragui

Auto-generated profile, based on publicly available information

Soufiane Mourragui

Hubrecht Institute-KNAW (Royal Netherlands Academy of Arts and Sciences)

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2024 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
MDMatheus Henrique. Dias
Matheus Henrique. Dias
AFAnoek Friskes
Anoek Friskes
SWSiying Wang
Siying Wang
JNJoao M. Fernandes Neto
Joao M. Fernandes Neto
FGFrank van Gemert
Frank van Gemert
RBRené Bernards
René Bernards
Cancer homeostasis depends on a balance between activated oncogenic pathways driving tumorigenesis and engagement of stress response programs that counteract the inherent toxicity of such aberrant signaling. Although inhibition of oncogenic signaling pathways has been explored extensively, there is increasing evidence that overactivation of the same pathways can also disrupt cancer homeostasis and cause lethality. We show here that inhibition of protein phosphatase 2A (PP2A) hyperactivates multiple oncogenic pathways and engages stress responses in colon cancer cells. Genetic and compound screens identify combined inhibition of PP2A and WEE1 as synergistic in multiple cancer models by collapsing DNA replication and triggering premature mitosis followed by cell death. This combination also suppressed the growth of patient-derived tumors in vivo. Remarkably, acquired resistance to this drug combination suppressed the ability of colon cancer cells to form tumors in vivo. Our data suggest that paradoxical activation of oncogenic signaling can result in tumor-suppressive resistance. Significance: A therapy consisting of deliberate hyperactivation of oncogenic signaling combined with perturbation of the stress responses that result from this is very effective in animal models of colon cancer. Resistance to this therapy is associated with loss of oncogenic signaling and reduced oncogenic capacity, indicative of tumor-suppressive drug resistance.

3 December 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
SMSoufiane M. C. Mourragui
Soufiane M. C. Mourragui
MLMarco Loog
Marco Loog
DVDaniel J. Vis
Daniel J. Vis
KMKat Moore
Kat Moore
AMAnna G. Manjon
Anna G. Manjon
LWLodewyk F. A. Wessels
Lodewyk F. A. Wessels
Significance: Cell lines have been extensively used to study anticancer agents, thereby establishing vast molecular and drug response datasets. Unfortunately, the translation of cell line–derived biomarkers often fails. To bridge this gap between model systems and clinical practice, we developed a mathematical framework to capture gene expression patterns shared between model systems and human tumors in a consensus space. In this space, we trained drug response predictors on a panel of 1,000 cell lines and successfully predicted drug response on approximately 1,300 human tumors. Finally, we derived an approach to interpret the predictors, and we propose potential mechanisms mediating the cytotoxic effects of two drugs. Experimental validation is required to confirm these results.

29 June 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
SMSoufiane Mourragui
Soufiane Mourragui
MLMarco Loog
Marco Loog
DVDaniel J. Vis
Daniel J. Vis
KMKat Moore
Kat Moore
AMAnna Gonzalez Manjon
Anna Gonzalez Manjon
LWLodewyk F.A. Wessels
Lodewyk F.A. Wessels
Pre-clinical models have been the workhorse of cancer research for decades. While powerful, these models do not fully recapitulate the complexity of human tumors. Consequently, translating biomarkers of drug response from pre-clinical models to human tumors has been particularly challenging. To explicitly take these differences into account and enable an efficient exploitation of the vast pre-clinical drug response resources, we developed TRANSACT, a novel computational framework for clinical drug response prediction. First, TRANSACT employs non-linear manifold learning to capture biological processes active in pre-clinical models and human tumors. Then, TRANSACT builds predictors on cell line response only and transfers these to Patient-Derived Xenografts (PDXs) and human tumors. TRANSACT outperforms four competing approaches, including Deep Learning approaches, for a set of 15 drugs on PDXs, TCGA cohorts and 226 metastatic tumors from the Hartwig Medical Foundation data. For only four drugs Deep Learning outperforms TRANSACT. We further derived an algorithmic approach to interpret TRANSACT and used it to validate the approach by identifying known biomarkers to targeted therapies and we propose novel putative biomarkers of resistance to Paclitaxel and Gemcitabine.

29 July 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
VBVivek Bhardwaj
Vivek Bhardwaj
SMSoufiane Mourragui
Soufiane Mourragui
Emerging single-cell sequencing protocols allow researchers to study multiple layers of epigenetic regulation while resolving tissue heterogeneity. However, despite the rising popularity of such single-cell epigenomics assays, the lack of easy-to-use computational tools that allow flexible quality control and data exploration hinders their broad adoption. We introduce the Single-Cell Informatics ( sincei ) toolkit. sincei provides an easy-to-use, command-line interface for the exploration of data from a wide range of single-cell (epi)genomics protocols directly from aligned reads stored in .bam files. sincei can be installed via bioconda and the documentation is available at https://sincei.readthedocs.io .

10 May 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
TATamim Abdelaal
Tamim Abdelaal
SMSoufiane Mourragui
Soufiane Mourragui
AMAhmed Mahfouz
Ahmed Mahfouz
Marcel ReindersMarcel Reinders
Marcel Reinders
Single-cell technologies are emerging fast due to their ability to unravel the heterogeneity of biological systems. While scRNA-seq is a powerful tool that measures whole-transcriptome expression of single cells, it lacks their spatial localization. Novel spatial transcriptomics methods do retain cells spatial information but can only measure tens to hundreds of transcripts. To resolve this discrepancy, we developed SpaGE, a method that integrates spatial and scRNA-seq datasets to predict whole-transcriptome expressions in their spatial configuration. Using five dataset-pairs, SpaGE outperformed previously published methods and showed scalability to large datasets. Moreover, SpaGE predicted new spatial gene patterns that are confirmed independently.

15 February 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
SMSoufiane Mourragui
Soufiane Mourragui
MLMarco Loog
Marco Loog
MRMarcel Jt Reinders
Marcel Jt Reinders
LWLodewyk Fa Wessels
Lodewyk Fa Wessels
Motivation: Cell lines and patient-derived xenografts (PDX) have been used extensively to understand the molecular underpinnings of cancer. While core biological processes are typically conserved, these models also show important differences compared to human tumors, hampering the translation of findings from pre-clinical models to the human setting. In particular, employing drug response predictors generated on data derived from pre-clinical models to predict patient response, remains a challenging task. As very large drug response datasets have been collected for pre-clinical models, and patient drug response data is often lacking, there is an urgent need for methods that efficiently transfer drug response predictors from pre-clinical models to the human setting.Results: We show that cell lines and PDXs share common characteristics and processes with human tumors. We quantify this similarity and show that a regression model cannot simply be trained on cell lines or PDXs and then applied on tumors. We developed PRECISE, a novel methodology based on domain adaptation that captures the common information shared amongst pre-clinical models and human tumors in a consensus representation. Employing this representation, we train predictors of drug response on pre-clinical data and apply these predictors to stratify human tumors. We show that the resulting domain-invariant predictors show a small reduction in predictive performance in the pre-clinical domain but, importantly, reliably recover known associations between independent biomarkers and their companion drugs on human tumors.Availability: PRECISE and the scripts for running our experiments are available on our GitHub page (https://github.com/NKI-CCB/PRECISE).Contact: l.wessels@nki.nlSupplementary information: Supplementary data are available. online.